Maraviroc

Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.

Product Specifications

CAS Number

[376348-65-1]

Product Name Alternative

UK-427857

UNSPSC

12352005

Hazard Statement

H373, H412

Target

CCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Maraviroc.html

Purity

99.98

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 6.5 mg/mL (ultrasonic)

Smiles

O=C(C1CCC(F)(F)CC1)N[C@H](C2=CC=CC=C2)CCN3[C@H]4C[C@@H](N5C(C)=NN=C5C(C)C)C[C@@H]3CC4

Molecular Formula

C29H41F2N5O

Molecular Weight

513.67

Precautions

H373, H412

References & Citations

[1]Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005 Nov;49 (11) :472|[2]Mencarelli A, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep. 2016 Aug 5;6:30802.|[3]Romero-Sánchez MC, et al. Effect of maraviroc on HIV-disease progression-related biomarkers. Antimicrob Agents Chemother. 2012 Nov;56 (11) :5858-64.|[4]Huilin Mou, et al. NRSF and CCR5 Established Neuron-glia Communication during Acute and Chronic Stresses. Journal of Drug Metabolism & Toxicology. January 10, 2016.